<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
April 6, 2000
-------------
CUBIST PHARMACEUTICALS, INC
---------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-21379 22-3192085
- --------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
24 Emily Street, Cambridge, Massachusetts 02139
-----------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (617) 576-1999
---------------
<PAGE>
ITEM 5. OTHER EVENTS.
On April 6, 2000, the Registrant, issued a press release announcing
that its public offering of 2,500,000 shares of Common Stock was priced at
$33.00 per share. The press release has been filed as an exhibit to this Report
on Form 8-K, attached hereto as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) EXHIBITS.
99.1 Press Release dated April 6, 2000
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CUBIST PHARMACEUTICALS, INC.
By: /s/ Thomas A. Shea
----------------------------------
Thomas A. Shea
Vice President, Finance and
Administration, Treasurer and Chief
Financial Officer
Dated: April 6, 2000
<PAGE>
EXHIBIT 99.1
CONTACTS:
CUBIST PHARMACEUTICALS, INC. NOONAN/RUSSO COMMUNICATIONS
SCOTT M. ROCKLAGE, PH.D. RENEE CONNOLLY (MEDIA)
CHAIRMAN, PRESIDENT & CEO (212) 696-4455 X227
(617) 576-4150 [email protected]
[email protected]
CUBIST PHARMACEUTICALS, INC. ANNOUNCES PRICING OF
SHARES FOR PUBLIC STOCK OFFERING
CAMBRIDGE, MA, APRIL 6, 2000 - Cubist Pharmaceuticals, Inc. (Nasdaq:CBST) today
announced that its public offering of 2,500,000 shares of Common Stock was
priced at $33.00 per share.
The company has also granted the underwriters an option to purchase up to an
additional 375,000 shares to cover over-allotments, if any.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or
jurisdiction. A copy of the prospectus may be obtained from FleetBoston
Robertson Stephens at 555 California St., San Francisco, CA 94104, (415)
781-9700.
FleetBoston Robertson Stephens served as lead managing underwriter and Pacific
Growth Equities, Inc., Chase H&Q, ING Barings and Lazard Freres & Co. LLC served
as co-managing underwriters for the offering.
Cubist Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the research, development and commercialization of novel antimicrobial drugs to
combat serious and life threatening bacterial and fungi infections. Cubist is
evaluating the efficacy and safety of daptomycin in the EDGE-TM- (Evaluation of
Daptomycin IN Gram-positive Entities) clinical trial program.
CUBIST SAFEHARBOR STATEMENT
STATEMENTS CONTAINED HEREIN THAT ARE NOT HISTORICAL FACTS MAY BE FORWARD-LOOKING
STATEMENTS (WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933 AND
SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934) THAT ARE SUBJECT TO A
VARIETY OF RISKS AND UNCERTAINTIES. THERE ARE A NUMBER OF IMPORTANT FACTORS THAT
COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE PROJECTED OR
SUGGESTED IN ANY FORWARD-LOOKING STATEMENTS MADE BY THE COMPANY. THESE FACTORS
INCLUDE, BUT ARE NOT LIMITED TO: (i) THE COMPANY'S ABILITY TO SUCCESSFULLY
COMPLETE PRODUCT RESEARCH AND DEVELOPMENT, INCLUDING PRE-CLINICAL AND CLINICAL
STUDIES AND COMMERCIALIZATION; (ii) THE COMPANY'S ABILITY TO OBTAIN REQUIRED
GOVERNMENTAL APPROVALS; (iii) THE COMPANY'S ABILITY TO ATTRACT AND/OR MAINTAIN
MANUFACTURING, SALES, DISTRIBUTION AND MARKETING PARTNERS; AND (iv) THE
COMPANY'S ABILITY TO DEVELOP AND COMMERCIALIZE ITS PRODUCTS BEFORE ITS
COMPETITORS. ADDITIONAL FACTORS THAT WOULD CAUSE ACTUAL RESULTS TO DIFFER
MATERIALLY FROM THOSE PROJECTED OR SUGGESTED IN ANY FORWARD-LOOKING STATEMENTS
IS CONTAINED IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE
COMMISSION, INCLUDING THOSE FACTORS DISCUSSED UNDER THE CAPTION "RISK FACTORS"
IN THE COMPANY'S REGISTRATION STATEMENT ON FORM S-3 (FILE NO. 333-32186).
For additional information, visit the Company's Internet web site at
http://www.cubist.com
